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Despite important advances in the understanding of the immune 
response in cancer, clinical investigations of cancer immunotherapies 
have had marginal success. Most immunotherapeutic agents did 
not show sufficient activity in early trials, and whereas some were 
advanced  to  phase  III  investigation,  most  failed  in  randomized 
comparisons (1). Likely contributing factors include ineffective 
or  marginally  effective  agents,  an  incomplete  understanding  of 
human tumor immunology, and the absence of adequate tools for 
development, including criteria for refined trial endpoints (1–3).
In  recent  years,  immunologic  science  has  evolved,  and  new 
mechanisms for targeted immunotherapies have been discovered 
(eg, immune checkpoint modulation such as anti-cytotoxic T 
lymphocyte–associated protein 4 [CTLA-4] or anti-programmed 
cell death-1 antibodies) (4–7). Adjusting the clinical development 
paradigm from chemotherapy to immunotherapy requires addressing 
the unique characteristics of immunotherapeutic agents in clinical 
trials to provide more adequate tools for evaluation (8), including 
the adjustment of clinical trial endpoints (9).
The continuum of biological events following administration 
of immunotherapy to a cancer patient can be divided into three 
steps: 1) immune activation and T-cell proliferation starting early 
after first administration, 2) clinically measurable antitumor effects 
mediated by activated immune cells over weeks to months, and 3) 
potential delayed effect on patient survival several months after 
first administration compared with agents not requiring immune 
activation (Table 1). Each biological event can be measured as a 
clinical trial endpoint and encompasses specific challenges.
The need to rethink clinical development of novel anticancer 
agents was recognized for solid tumors and hematologic malig-
nancies (8–11), in particular for prostate cancer (12–14), melanoma 
(15–17), or lymphoma (18,19). From 2004 to 2009, several initiatives 
systematically evaluated an immunotherapy-focused clinical devel-
opment paradigm, which supported the redefinition of biological 
outcome measures and clinical endpoints (2,8,9,20–22). These initia-
tives were planned and facilitated by the Cancer Immunotherapy 
Consortium of the Cancer Research Institute (CIC-CRI; formerly 
Cancer Vaccine Consortium) and conducted in collaboration with 
the Association for Cancer Immunotherapy (C-IMT) in Europe or 
the International Society for Biological Therapy of Cancer in the 
United States. Workshops or expert panels summarized community 
knowledge and defined challenges as a platform for improvements 
in trial endpoints. This knowledge was then used to systematically 
generate  large  datasets  or  analyze  existing  datasets  with  the   
aim of improving conventional endpoints. Several CIC-CRI and 
C-IMT proficiency panels identified sources of variability of T 
cell–response assays and defined harmonization criteria to con-
trol variability without limiting individual laboratory protocols. 
A large clinical trial program (n = 487) conducted by Bristol-
Myers  Squibb  and  Medarex  investigated  antitumor  response 
and survival outcomes to propose new response criteria, as well 
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Unlike chemotherapy, which acts directly on the tumor, cancer immunotherapies exert their effects on the immune system and 
demonstrate new kinetics that involve building a cellular immune response, followed by changes in tumor burden or patient 
survival. Thus, adequate design and evaluation of some immunotherapy clinical trials require a new development para-
digm that includes reconsideration of established endpoints. Between 2004 and 2009, several initiatives facilitated by the 
Cancer Immunotherapy Consortium of the Cancer Research Institute and partner organizations systematically evaluated an 
immunotherapy-focused clinical development paradigm and created the principles for redefining trial endpoints. On this basis, 
a body of clinical and laboratory data was generated that supports three novel endpoint recommendations. First, cellular 
immune response assays generate highly variable results. Assay harmonization in multicenter trials may minimize variability 
and help to establish cellular immune response as a reproducible biomarker, thus allowing investigation of its relationship with 
clinical  outcomes.  Second,  immunotherapy  may  induce  novel  patterns  of  antitumor  response  not  captured  by  Response 
Evaluation Criteria in Solid Tumors or World Health Organization criteria. New immune-related response criteria were defined 
to more comprehensively capture all response patterns. Third, delayed separation of Kaplan–Meier curves in randomized immu-
notherapy trials can affect results. Altered statistical models describing hazard ratios as a function of time and recognizing 
differences before and after separation of curves may allow improved planning of phase III trials. These recommendations may 
improve our tools for cancer immunotherapy trials and may offer a more realistic and useful model for clinical investigation.
J Natl Cancer Inst 2010;102:1388–1397jnci.oxfordjournals.org    JNCI | Review 1389
as statistical methods more suitable for the analysis of survival 
kinetics.
Three  novel  endpoint  considerations  for  immunotherapy 
investigation, which need to undergo prospective evaluation in 
clinical studies (9), were formulated as follows. First, minimize 
variability of T-cell assay results through assay harmonization to 
establish cellular immune response as a reproducible biomarker 
and subsequently investigate its relationship with clinical out-
comes.  Second,  capture  the  spectrum  of  clinical  patterns  of 
antitumor response for immunotherapeutic agents through novel 
immune-related response criteria (irRC), which are adapted from 
Response Evaluation Criteria in Solid Tumors (RECIST) and 
World Health Organization (WHO) criteria. Third, use different 
statistical methods for trial design and analysis of survival out-
comes in the presence of delayed separation of Kaplan–Meier 
survival curves.
The core aspects of these recommendations were discussed at a 
Workshop of the United States Food and Drug Administration in 
2007 and were included in a recently issued guidance document 
“Clinical Considerations for Therapeutic Cancer Vaccines,” thus 
providing developmental guidance to developers of immunother-
apies (23). Taken together, these recommendations represent an 
expansion of methodology for cancer immunotherapy trials and 
may contribute to improved clinical investigations.
Measuring Immune Response: Reduction of 
Variability Through Assay Harmonization
Activation of the cellular arm of the immune system is seen as 
the first biological event after administration of immunotherapy, 
and consequently, measurement of such a response (mostly T-cell 
response) is of great interest. A variety of bioassays exist for 
immune monitoring, including the enzyme-linked immunosorbent 
spot (ELISPOT) assay and cytometry-based tests such as intracel-
lular cytokine staining, HLA-peptide multimer staining, and the 
carboxyfluorescein succinimidyl ester assay (24–27). Even though 
the  fundamentals  of  these  assays  have  been  well  established,  a 
plethora of different laboratory protocols is used (24,27,28).
Substantial  variability  in  results  among  laboratories  exists  in 
multicenter  trials,  which  hampers  data  reproducibility  and  pre-
vents meaningful comparisons among studies (28). For example, in 
the first CIC-CRI ELISPOT proficiency panel, 36 laboratories 
used the ELISPOT assay to analyze the same donor peripheral 
blood  mononuclear  cell  sample  for  a  T-cell  immune  response, 
resulting in spot counts ranging from nondetectable to strongly 
positive (Figure 1). The challenge is the absence of a quality control 
measure for T cell–based assays that can be used as a gold standard 
(29), which has prevented the field from establishing T-cell response 
as a biomarker for immunotherapy trials and conducting reliable 
investigations of its relationship with clinical outcomes (30).
Under  the  auspices  of  CIC-CRI  and  C-IMT,  two  large   
international  immune  monitoring  proficiency  panel  programs 
were initiated in 2005 (20–22). Their goals were to provide an 
external  quality  assurance  process  for  laboratories  conducting   
immune  monitoring  in  clinical  trials  and  to  harmonize  assay   
performance.  Harmonization  of  clinical  trial  conduct  and  data 
collection as established through the International Conference on 
Harmonization for Good Clinical Practice had previously proven 
to be a highly successful model for improving clinical development 
procedures (31).
Proficiency panels are quality control experiments in which the 
same patient samples are tested across multiple laboratories, using 
their respective protocols, and the results are centrally evaluated 
(32). The CIC-CRI proficiency panel program is led by a scientific 
steering committee and involves a central laboratory for accrual of 
peripheral blood mononuclear cells, shipping logistics, and inde-
pendent central data analysis. Peripheral blood mononuclear cell 
samples  and  antigens,  pretested  and  defined  for  their  response 
status,  are  sent  to  all  participating  laboratories,  where  they  are 
tested for response under the local conditions. Test results and 
Table 1. Challenges and recommendations for assessment of cancer immunotherapy*
Immunotherapy start
Immune cell activation and  
proliferation Effect on tumor Effect on survival
Day 1 Days to weeks Weeks to months Several months
Endpoint Cellular immune response Antitumor response Survival
Challenges Complex assays exist 
Results are highly variable and not  
  reproducible across trials 
Assay procedures are not  
  harmonized
Conventional and novel response  
  patterns are observed 
The translation of the immune  
  response into an antitumor  
  response takes time 
No systematic criteria to capture  
  new response patterns exist
Translation of immune and antitumor 
  response into a survival effect  
  takes time 
Proportional hazards assumptions  
  are not applicable 
Conventional statistical models do  
  not account for nonproportional  
  hazards and delayed separation of  
  curves
Recommendations Harmonized assay use through  
  SOPs that accompany individual  
  assay protocols
Identify relevant response  
  patterns
Employ statistical models that  
  account for the delayed effect
Use systematic criteria (irRC) to  
  reproducibly capture new  
  patterns
Carefully consider use of early  
  interim and futility analyses
*  irRC = immune-related response criteria; SOP = standard operating procedure.1390   Review | JNCI  Vol. 102, Issue 18  |  September 22, 2010
combined  panel  results  led  to  initial  ELISPOT  harmonization 
guidelines (Table 2) (20), which synchronize key variables across 
laboratories and substantially influence assay outcome but do not 
impose standardization of assays on individual laboratories. The 
introduction of these guidelines is central to this harmonization to 
provide general assistance for the conduct of the individual assay 
protocol  in  the  context  of  standard  operating  procedures  (eg, 
exclusion of apoptotic cells, use of pretested serum for background 
reduction,  and  quality  control  during  the  computerized  spot 
evaluation) (Table 2) (20). Confirmatory findings from a parallel 
experiment were published by the C-IMT proficiency panels (21). 
As the use of serum is a crucial variable for ELISPOT assays, a 
separate ELISPOT proficiency panel focused on serum use and 
showed that serum-free medium for incubation of cells can be as 
effective as qualified serum-supplemented medium, thus address-
ing this crucial variable for assay protocols as part of the harmoni-
zation guidelines (33).
The first round of the HLA-peptide multimer-staining panel of 
CIC-CRI allowed the formulation of initial harmonization guide-
lines (22), which will likely reduce assay variability. These recom-
mendations are 1) the use of more than two colors for staining, 2) 
protocol details are reported back for central analysis. Since 2005, 
more than 80 laboratories from 14 countries have participated, 
encompassing  the  academic,  nonprofit,  biotech,  and  pharma-
ceutical sectors, and the United States Department of Defense 
(20,22).
The ELISPOT panel is the longest running program and pro-
vides the most mature results. The objective of the first ELISPOT 
panel was to identify sources of variability among assay procedures. 
The  second  panel  adjusted  these  sources  of  variability  while 
keeping  the  respective  laboratory  protocols  intact.  This  adjust-
ment led to a substantial reduction in variability: The percentage 
of  participants  unable  to  detect  all  responders  (six  responders 
among eight samples) was reduced from 47% to 14%, and the 
percentage of participants unable to detect 50% or more of all 
responders (“outliers”) dropped from 11% to 0% (Figure 2). The 
Figure 1. High variability of results for the enzyme-linked immunosorbent 
spot  (ELISPOT)  immune  response  assay.  Identical  peripheral  blood 
mononuclear cell samples from the same patient were sent to 36 
different laboratories experienced with ELISPOT methodology. The 
image shows the spot count results in microtiter plates in which each 
well  represents  the  result  of  one  laboratory.  Some  wells  show  high 
numbers of spots, whereas others are low or negative. Each spot in this 
assay represents a single T-cell capable of reacting against a defined target 
antigen. These results reflect the outcome of the first ELISPOT profi-
ciency panel, which identified sources of variability among laboratories.
Table 2. Initial harmonization guidelines for the enzyme-linked 
immunosorbent spot (ELISPOT) immune response assay*
A Use only pretested and optimized serum allowing for low  
  background : high signal ratio
B Establish laboratory SOP for ELISPOT testing procedures,  
  including:
  B1 Counting method for apoptotic cells for determining  
  adequate cell dilution for plating
  B2 Overnight rest of cells before plating and incubation
C Establish SOP for plate reading, including:
  C1 Human auditing during reading process
  C2 Adequate adjustments for technical artifacts
D Only allow trained personnel, certified per laboratory SOP,  
  to conduct assays
*  Harmonization guidelines can be used by each individual laboratory performing 
an immune response assay in the context of Standard Operating Procedures 
(SOPs) and without adopting a standard assay protocol. Through general 
steps such as use of pretested serum [or serum-free media (33)], exclusion 
of apoptotic cells from the analysis, human auditing of the computerized 
assay read out procedure, and training of operators on the laboratory SOPs, 
quality of assays can be substantially improved. Courtesy of Janetzki et al. (20).
Figure  2.  Effect  of  assay  harmonization  on  data  variability  of  the 
enzyme-linked  immunosorbent  spot  (ELISPOT)  assay.  In  the  Cancer 
Immunotherapy Consortium of the Cancer Research Institute ELISPOT 
proficiency panel, participating laboratories reported the response 
status from eight different donor–antigen combinations. Grey bars rep-
resent the first panel round and stippled bars the second panel round. 
In the first panel round, 47% of panelists missed detection of at least 
one response correctly, and 11% of panelists failed to detect at least 
three responses correctly (characterized as an “outlier” because of high 
variability). Based on the first panel results, harmonization criteria were 
given to panelists, and the testing was repeated in the second panel 
(stippled bars). ELISPOT performance improved, with only 14% of pan-
elists missing at least one responder and zero outliers.jnci.oxfordjournals.org    JNCI | Review 1391
the collection of more than 100 000 CD8 T cells, and 3) the use of 
a background control sample to set appropriate analytical gates 
(data points of interest) (22). The second CIC-CRI panel round 
focused on confirmation of these guidelines, as well as assessment 
of the influence of specific protocol steps on final results.
The first intracellular cytokine staining panel was conducted 
under highly standardized conditions. However, the results dem-
onstrated that the use of standardized reagents and protocols 
alone does not lead to the desired performance among panelists. 
The ongoing second panel allows free choice of reagents and 
protocols but requires compliance with evolving minimum guide-
lines based on the results of the first panel. Results are expected 
later in 2010.
The clinical trial application of immune assays was addressed 
by an international working group, the Cancer Vaccine Clinical 
Trial Working Group (8), which proposed that immunoassays in 
clinical trials should be performed at least at three different time 
points throughout any study—one baseline and two follow-up 
time points. Assays should be established, reproducible, and tech-
nically  (not  clinically)  validated  in  the  respective  laboratories 
(according to the harmonization criteria for respective assays). At 
least two assays should be used in parallel to demonstrate the 
same findings (eg, ELISPOT and HLA-peptide multimer stain-
ing), which is particularly important if developmental decisions 
(eg, moving a new agent into more advanced trials) would be 
based on immune response data from such assays. Moreover, the 
cutoff values for an immune response should be identified pro-
spectively to define the change necessary for a response and to 
define the proportion of study patients needed for a positive 
study outcome.
In addition, a separate initiative is under way to provide a pub-
lication framework for the results from immune monitoring trials. 
This project, named MIATA (minimal information about T-cell 
assays), is currently undergoing a public consultation process   
to obtain community feedback (28). Overall, only when the issue 
of current assay variability is adequately addressed can cellular 
immune response become a reliable parameter in clinical trials 
and may be more reliably studied for its relationship with clinical 
outcomes.
Measurement of Antitumor Response: irRC
For decades, investigators have relied on modified WHO criteria 
(34) or, more recently, RECIST (35,36) to assess clinical activity 
of  anticancer  agents.  These  standard  criteria  were  designed  to 
capture effects of cytotoxic agents and depend on tumor shrinkage 
to demonstrate activity. However, the response patterns seen 
with immunotherapeutic agents extend beyond those of cytotoxic 
agents  and  can  manifest,  for  example,  after  a  period  of  “stable 
disease” in which there is no tumor shrinkage or after initial tumor 
burden  increase  or  appearance  of  new  lesions  (eg,  tumor  infil-
trating lymphocytes) (15,37–40).
This potential delayed detection of clinical activity on radio-
graphic  assessment  may  reflect  the  dynamics  of  the  immune 
system—the time required for T-cell expansion followed by infil-
tration of the tumor—and a subsequent measurable antitumor 
effect. For example, some reported clinical experiences with cancer 
vaccines (37–39) demonstrated that patients with stable disease 
or progressive disease may have subsequent tumor regression, 
whereas others may show initial mixed responses, with regression 
in some lesions while other lesions remain stable, progress, or first 
appear. In these studies, patients with measurable tumor burden 
decrease had more responses that did not fit currently accepted 
response  criteria  than  conventional  responses  (eg,  5/6  and  4/5 
unconventional out of all recorded responses) (37–39). Such pat-
terns have been noted by many investigators; however, they were 
inconsistently included in publications or were not systematically 
captured because of the absence of suitable response criteria (8), 
which, in turn, did not allow for their clinical significance to   
be adequately studied (8). It has become evident that RECIST 
or WHO criteria may not offer a complete description of the 
response to immunotherapeutic agents, and either adjusted or new 
criteria are needed (8).
Similar  to  the  immune  response  assays  discussed  above,  the 
Cancer Vaccine Clinical Trial Working Group addressed the topic 
of  clinical  endpoints  and  potential  delayed  detection  of  clinical 
activity in a series of workshops. The main conclusions were that 
the appearance of measurable clinical activity at the tumor site may 
take longer for immunotherapies than for cytotoxic therapies; 
responses  to  immunotherapies  may  occur  after  conventional 
progressive disease (tumor burden increase); discontinuation of 
immune  therapy  may  not  be  appropriate  in  some  cases,  unless 
progressive disease is confirmed (as is usually done for RECIST-
based response); there should be allowance for “clinically insignif-
icant” progressive disease (eg, small new lesions in the presence of 
other responsive lesions); and durable stable disease may represent 
clinical benefit. Such elements might be included in new antitumor 
response criteria that adapt standard criteria to the unique charac-
teristics of immunotherapy (8).
Building on these recommendations, a novel set of response 
criteria based on WHO and RECIST were evaluated in a series of 
large multinational studies (17,41,42), including 487 patients with 
advanced melanoma participating in the Bristol-Myers Squibb and 
Medarex  clinical  trial  program  for  ipilimumab,  a  fully  human 
monoclonal antibody that blocks CTLA-4. In these studies, four 
distinct  response  patterns  were  detected:  immediate  response, 
durable stable disease, response after tumor burden increase, and 
response in the presence of new lesions (Figure 3). The first two 
patterns are conventional (Figure 3, A and B), whereas the latter 
two (Figure 3, C and E) are novel and specifically recognized with 
immunotherapeutic agents. Photographs of a case study of the first 
novel tumor response pattern (Figure 3, D) show that tumor bur-
den initially increases (day 84) and then decreases (day 112) to a 
complete response (day 503). Importantly, all patterns (conven-
tional and new) seem to be associated with favorable survival com-
pared  with  patients  with  progressive  disease  by  WHO  criteria 
(43,44).  To  create  a  process,  which  systematically  captures  all 
observed response patterns, irRC were proposed (43–45).
The irRC enhance characterization of immunotherapy response 
patterns through new features. In particular, they allow for the 
assessment of tumor burden as a continuous variable, which con-
siders index lesions identified at baseline together with new lesions 
as they may occur after treatment start. Only measurable lesions 
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for each lesion. Measurability is defined as 5 × 5 mm or more on 
helical computer tomography scans. The sum of the perpendicular 
diameters (SPD) of index lesions at baseline is added to that of new 
lesions to calculate total tumor burden according to the following 
formula:
   index lesions  new measurable lesions Tumor Burden = SPD +SPD .
Thus, percentage changes in tumor burden between assessment 
time points describe the size and growth kinetics of total measur-
able tumor burden over time. Response categories under irRC are 
defined  as  immune-related  complete  response  (irCR),  immune-
related partial response (irPR), immune-related stable disease 
(irSD), and immune-related progressive disease (irPD) using the 
same thresholds to distinguish between categories as defined under 
standard WHO criteria (Table 3). Decrease in total measurable 
tumor burden is assessed relative to the baseline tumor burden, 
that is, SPD of all index lesions at baseline. The response category 
irPD  should  be  confirmed  at  two  consecutive  time  points  as 
already done for irPR or irCR. Overall, immune-related response 
based on two or more tumor assessments is derived as shown in 
Table 3.
Using irRC, the appearance of new lesions alone does not con-
stitute irPD if they do not add to the tumor burden by at least 
Figure  3.  Clinical  response  patterns  observed  with  anti-cytotoxic  T 
lymphocyte–associated protein 4 immunotherapy (ipilimumab). Immuno-
therapy patterns of response depicted as a continuous variable of rela-
tive change of tumor burden (%) over time. Tumor burden is described 
through the sum of the perpendicular diameters (SPD) of all measur-
able lesions (baseline and new) at each time point. A and B) Conventional 
response patterns: (A) immediate response; (B) durable stable disease 
with possible slow decline in tumor burden. C and E) Novel immuno-
therapy response patterns: (C) increase in total tumor burden followed 
by response. (D) Clinical images corresponding to pattern (C): tumor 
burden on the skin at baseline (day 0) is increased at first follow-up 
(day 84) and subsequently declines (day 112) to a complete response 
(day 503) (courtesy of Dr K. Harmankaya). E) The second novel pat-
tern  shows  a  response  in  the  presence  of  new  lesions;  existing   
lesions present at baseline (blue) and new lesions (red) are added to 
define the total tumor burden (green). Despite new lesions, the total 
tumor burden is still declining to a partial response. Yellow triangles 
indicate dosing with immunotherapy; horizontal lines indicate stan-
dard thresholds for response or progression. Modified after Wolchok 
et al. (43).jnci.oxfordjournals.org    JNCI | Review 1393
25%. Patients with new lesions but an overall tumor burden 
decrease qualifying for partial response (≥50% decrease) or quali-
fying for stable disease (<50% decrease to >25% increase) are 
considered to have irPR or irSD, respectively (same percentage 
changes including new lesions) (Table 3). These new patterns are 
considered clinically meaningful because they appear to be associ-
ated with favorable survival (43,44). Importantly, early increase in 
the size of lesions, which may be attributable to the infiltration of 
lymphocytes, does not preclude an irCR, irPR, or irSD from being 
obtained at the next consecutive time point. If a patient is classified 
as having irPD, confirmation by a second scan in the absence of 
rapid clinical deterioration is required. Thus, the definition of 
confirmation  of  progression  represents  an  increase  in  tumor 
burden of at least 25% compared with baseline at two consecu-
tive time points at least 4 weeks apart. It is recommended that 
this confirmation be done at the discretion of the investigator in 
the context of the patient’s tumor type, disease stage, and clin-
ical  status  because  awaiting  a  response  after  tumor  burden 
increase may not be appropriate for patients with rapid symp-
tomatic progression accompanied by a decline in performance 
status.
In summary, the development of irRC may provide a novel 
and long-needed tool for clinical trials to assess signs of activity 
of immunotherapies. Because data obtained with ipilimumab (43) 
suggest an association of immune-related response patterns with 
favorable patient survival, these criteria may identify important 
clinical patterns otherwise characterized as progressive disease 
by  WHO  criteria.  Further  prospective  evaluation  of  irRC  in 
immunotherapy trials is required to confirm their clinical utility. 
Complete details of the new irRC are described by Wolchok   
et al. (43).
Table 3. Derivation of overall immune-related response in solid 
tumors*
Derivation of overall immune-related response for all assessed 
time points
Measurable response Nonmeasurable response
Overall 
response
Index and new measurable 
lesions (total measurable 
tumor burden)†
Non-index  
lesions
New  
nonmeasurable  
lesions
Using 
irRC
100% decrease Absent Absent irCR‡
≥50% decrease Any Any irPR‡
<50% decrease to <25%  
  increase
Any Any irSD
≥25% increase Any Any irPD‡
*  After Wolchok et al. (43). irCR = immune-related compete response—
complete disappearance of all index and new measurable lesions; irPR = 
immune-related partial response—decrease in tumor volume ≥50% relative to 
baseline; irSD = immune-related stable disease—not meeting criteria for irCR 
or irPR, in absence of irPD; irPD = immune-related progressive disease—
increase in tumor volume ≥25% relative to nadir.
†  Index and non-index lesions are selected at baseline. Index lesions are mea-
surable (>5 × 5 mm), and non-index lesions are not measurable (<5 × 5 mm, 
ascites, bone lesions, etc.). Changes are assessed relative to baseline and 
include measurable lesions only (>5 × 5 mm).
‡  Assuming response and progression are confirmed by a second assessment 
at least 4 weeks apart.
Figure 4. Delayed separation of survival curves of sipuleucel-T immuno-
therapy vs placebo in advanced prostate cancer, where the separation 
of Kaplan–Meier curves occurred after approximately 8 months after 
random  assignment.  HR  =  hazard  ratio;  CI  =  confidence  interval. 
Courtesy of Small et al. (12). Reprinted with permission. Copyright 2008 
American Society of Clinical Oncology. All rights reserved.
Survival Kinetics: Differences Between 
Immunotherapy and Conventional Therapies
In contrast to chemotherapy, for which an early clinical effect is 
possible,  immunotherapies  often  demonstrate  delayed  clinical 
effects (12,14,17,46–49). For example, Figure 4 shows the overall 
survival outcome for a study of sipuleucel-T immunotherapy vs 
placebo in advanced prostate cancer (12), where the separation of 
Kaplan–Meier curves occurs after approximately 8 months after 
random assignment. In randomized trials, in which immuno-
therapies are compared with either placebo or inactive controls, 
Kaplan–Meier survival curves may be superimposable for a time 
before  separation  is  observed.  Generally,  if  there  is  such  a 
delayed separation, the statistical power to differentiate the entire 
curves is reduced (1,9,50).
To better understand possible lessons from existing datasets of 
phase III immunotherapy trials, a workshop of the CIC-CRI in 
2006 reviewed all publicly accessible data from such trials. This 
analysis  suggested  the  possibility  of  a  delayed  separation  of 
Kaplan–Meier curves for immunotherapeutic agents (mostly can-
cer vaccines) (1), including melacine in stage II melanoma (46), 
vitespen in advanced melanoma (47), vitespen in stage II/III renal 
cell carcinoma (48), sipuleucel-T (12) (Figure 4), PROSTVAC-VF 
(14) in advanced prostate cancer, and the anti-CTLA-4 antibody 
ipilimumab in advanced melanoma (17,49). A separation of curves 
in these trials was observed after 4–8 months or later following 
random  assignment.  However,  such  kinetics  may  differ  among 
agents and disease settings, thus requiring individual investigation.
The survival analysis methods commonly used to design and 
analyze two-arm randomized clinical trials do not have a provision 
for data demonstrating a delay in the separation of Kaplan–Meier 
curves. These methods assume that the ratio of the arm-specific 
hazard rates (risks for patients to experience events) is a constant 
over time (proportional hazards assumption) and is necessary when 
using the standard formula for computing the number of events 
required for the final analysis of a trial (51). Furthermore, the log-
rank test has optimal properties under proportional hazards, and 
Cox regression models assume proportional hazards. Under these 1394   Review | JNCI  Vol. 102, Issue 18  |  September 22, 2010
separation. The control arm has an exponential survival distribution 
with median survival of 18 months (red dashed curve). The form 
of the delayed separation is specified by a hazard ratio function 
(HR(t), solid grey line) that has value 1.0 for the first 3 months and 
then decreases linearly between 3 and 6 months to become 0.7 
after 6 months. The experimental arm survival distribution (solid 
blue line) is the result of mathematically blending the control arm 
survival distribution function and the hazard ratio function. The 
survival distributions in Figure 5 can be used to illustrate the con-
sequences of delayed separation. The following additional specifi-
cations are made: 1:1 random assignment, N = 600, accrual time 18 
months, two-sided type I error probability .05, statistical power of 
90%, and use of the log-rank statistic. Under proportional hazards 
(no delayed separation), 331 events are required for final analysis 
and are projected to occur at 2.85 years. With a delayed separation 
to 3 months as specified, 331 events would result in a statistical 
power estimate of only 62.7%. Using simulations that take into 
account delayed separation, it is found that 90% statistical power 
requires 510 events and would not be realized until 5.66 years.
It is therefore recommended that the computations of the 
required events be based on a plausible specification of the timing 
of the delayed separation, the desired statistical power, use of the 
log-rank statistic, and the understanding that the trial will be over-
powered if delayed separation is not observed or is less than that 
specified. The log-rank test is recommended for study planning 
and final analysis to avoid deviation from conventional methods, to 
avoid prespecification of parameters describing the delay (52,53), 
and as a hedge against absence of a delay. The cost of using the 
log-rank statistic is some loss of optimal conditions if a delay is 
present. Because immunotherapeutic agents may differ regarding 
presence and timing of delayed separation, randomized phase II 
trials may improve the ability to plan for definitive phase III trials.
Further challenges include the planning of interim and futility 
analyses. These must be carefully considered because the presence 
of a delayed separation will inflate the chances of a negative early 
interim  analysis  and  of  concluding  futility  because  of  projected 
results without a delayed separation.
Conclusions
As our knowledge of immunologic and clinical science has evolved 
(4–7), we have begun to address the unique characteristics of im-
munotherapeutic agents in clinical trials and to use more appro-
priate  endpoints  (8,9,10,43).  Immunotherapies  demonstrate 
different kinetics compared with cytotoxic agents. Thus, they may 
induce cellular immune responses before influencing tumor burden 
or patient survival (8,9). For adequate investigation of immuno-
therapies in clinical trials, a new development paradigm is needed, 
including adjustment of established endpoints to address this 
biology. The challenges around adequate clinical endpoint use in 
immunotherapy  trials  were  addressed  through  community-wide 
workshops paired with comprehensive laboratory and clinical pro-
grams providing large datasets (8,9,17,20–22,41,42).
The inability to use cellular (T-cell) immune response assays to 
define biomarkers and to investigate their relationship with clinical 
outcomes has its roots in highly variable and often nonreproduc-
ible assay results in multicenter trials (28,30). As was demonstrated 
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Figure 5. Mathematical illustration of a delayed separation of curves. 
Example of a two-arm study with an ultimate hazard ratio of 0.7. The 
control arm has an exponential survival distribution with median sur-
vival of 18 months (red dashed curve). The form of the delayed separa-
tion is specified by a hazard ratio function (HR(t), solid gray line) that 
has the value 1.0 for 3 months and then decreases linearly between 3 
and 6 months to become 0.7 at 6 months and then remains constant. 
The  experimental  arm  survival  distribution  (solid  blue  line)  is  the 
consequence  of  mathematically  blending  the  control  arm  survival 
distribution function and the hazard ratio function.
assumptions, the hypothesized hazard ratio (HR), describing the 
difference in survival between the study arms, applies immediately 
after random assignment, and the event rates at all times will have 
the same ratio to differentiate between the arms.
Delayed separation is a form of deviation from proportional 
hazards. Initially, the hazard rates are equal, and therefore, the 
hazard ratio is 1.0, and the Kaplan–Meier curve estimates will be 
indistinguishable (if an inactive comparator is used). Subsequently, 
the hazard rates become unequal and the curves will separate. For 
practical purposes, it is assumed for this discussion that the hazard 
rates after the delayed clinical effect eventually become propor-
tional. Thus, the events occurring before the time when the hazard 
rates become unequal will not differentiate the study arms. As a 
consequence, computation of the required number of events for 
final analysis under proportional hazards assumptions will lead to 
a statistical power insufficient for a trial with a delayed separation. 
Depending on the timing of the delay, this loss of statistical power 
can be substantial (1,9,50).
Alternative  methods  should  be  considered  to  compute  the 
required number of events for final analysis when delayed separa-
tion is expected (1,9). A variety of methods including simulation 
and numerical integration of a proposed theoretical hazard func-
tion can be used. Simulation is attractive because it may also 
account for other deviations from usual trial planning assumptions. 
However, any method used to compute the required number of 
events will require careful scrutiny and validation. Another critical 
element for the computation of the number of events is the timing 
(quantification) of the delayed effect. Ideally, the quantification 
used to compute the required events will come from previous ran-
domized trials, possibly in the phase II setting (9).
The following example illustrates the practical implications 
of the delayed separation on study statistical power, number of 
events, and study duration. Figure 5 illustrates the mathematical 
form of a delayed separation, with a hazard ratio of 0.7 after the jnci.oxfordjournals.org    JNCI | Review 1395
by  several  large  international  proficiency  panels,  the  use  of   
harmonized assays can reduce this variability (20–22) and may 
help to build a general framework for assay use in multicenter 
clinical  trials  similar  to  what  the  International  Conference  on 
Harmonization/Good Clinical Practice did for clinical protocols. 
Furthermore, harmonized assays may allow investigation of the 
relationship  between  immune  responses  and  clinical  outcomes. 
Correlation  of  immune  response  and  clinical  outcomes  would 
certainly accelerate the learning process regarding the biological 
activity of immunotherapeutic agents in the clinic and help the 
early selection of promising candidates for advanced trials.
As observed in many clinical trials, immunotherapy can induce 
novel  patterns  of  antitumor  responses  distinct  from  those  of 
chemotherapy, which are consequently not captured by the WHO 
or RECIST criteria. In a 5-year collaborative effort between 
academia and industry (8,44), clinical observations were translated 
into new response criteria (43), which more comprehensively cap-
ture all observed response patterns. The irRC provide a systematic 
description for phenomena such as mixed responses, in which new 
lesions appear while existing lesions shrink or in which some 
lesions shrink while others grow. Through the new irRC system, 
immunotherapy  patterns  of  response  are  described  as  tumor 
burden over time where tumor burden is the SPD of all measur-
able lesions (baseline and new). The irRC are generally based on 
the WHO and RECIST criteria and do not require a substantial 
departure from standard oncology practice. The novelty of the 
irRC lies in the measurement of new lesions, which are included in 
the overall tumor burden, allowing for it to be described as a con-
tinuous variable (before and after conventional progression) (9,44). 
This response analysis bears similarities to a concept described for 
the investigation of cytostatic agents such as sorafenib, in which 
tumor size was described as a continuous variable (54).
Histological  evidence  in  cases  in  which  biopsy  material  was 
available suggests that the appearance of new lesions or increase in 
the  size  of  existing  lesions  may  be  the  result  of  lymphocytic 
infiltration and may not represent true disease progression (40,55). 
In these cases, the irRC provide a means of accounting for delayed 
changes in tumor burden through confirmation of progression at 
subsequent time points. This new confirmation of progression is 
similar to the confirmation routinely done for response and may 
enable the detection of a change in kinetics when initial tumor 
burden increase through lymphocytic infiltration is followed by a 
lymphocyte-induced tumor response (delayed response). Importantly, 
initial observations in advanced melanoma with anti-CLTA-4 
antibody indicate an association of immune-related responses 
with favorable survival, suggesting that these criteria may identify 
patients with previously unrecognized benefit (43,44). The clinical 
applicability of these criteria lies principally in the more compre-
hensive description of clinical signals of activity in early trials. 
Consequently, the irRC offer an additional tool for investigating 
immunotherapies and are undergoing prospective validation.
Considering the time of translation of immunologic responses 
into clinical activity, the survival of patients may not be affected 
until some months after treatment start compared with chemo-
therapy. A resulting delayed separation of Kaplan–Meier curves 
was observed in multiple randomized immunotherapy trials and 
was often not apparent until 4–8 months or more after random 
assignment (12,14,17,46–49). In patient populations with advanced 
cancers, a substantial number of events can occur in the time win-
dow before separation and thus lead to substantial loss of statistical 
power (1,9,50). Whereas it remains unclear whether past studies 
would have had a different outcome if delayed separation had been 
considered during trial planning, its consideration for future eval-
uations appears important. Knowledge of survival kinetics may also 
allow better planning of interim analyses because if they are per-
formed too early, they may give misleading results and conclude 
futility prematurely. In addition, immunotherapeutic agents may 
differ in the timing of delayed separation and should be tested in 
randomized phase II trials to improve the planning for phase III 
trials.  Use  of  modified  statistical  methods  to  characterize  the   
hazard ratios before and after separation of survival curves allows 
improved planning of randomized trials in which a delayed separa-
tion of curves is expected.
In  summary,  the  described  recommendations  for  improved 
clinical endpoints have the potential to positively alter the clinical 
investigation of cancer immunotherapy.
Supplementary Data
Supplementary data can be found at http://www.jnci.oxfordjournals 
.org/.
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